The short version
A new exploratory MRI analysis of the SmartAge randomized trial reports that 12 months of spermidine supplementation (0.9 mg/day) was associated with higher blood flow in the precuneus, a region central to memory and self-referential thought. It was also associated with steadier white-matter microstructure in the cingulate gyrus. The catch is important: the changes did not track with memory performance, and the parent SmartAge trial did not find a memory benefit. Published in Aging and Disease (Schwarz et al., 2026), this is a hypothesis-generating result, not proof that spermidine protects the aging brain.
What the researchers did
SmartAge was a randomized, double-blind, placebo-controlled trial in adults aged 60 to 90 with subjective cognitive decline (SCD), meaning they felt their thinking was slipping even when standard testing might not clearly show impairment. SCD is a group of interest because it can, in some people, precede measurable decline.
Participants took either 0.9 mg of spermidine per day or placebo for 12 months. This MRI analysis included 75 participants and examined vascular brain health markers:
- Cerebral blood flow (CBF)
- White-matter microstructure (fractional anisotropy, FA)
- White-matter hyperintensities (WMH)
The team also looked at brain volume and cortical thickness. Statistical models were adjusted for age, sex, and baseline measures.
What they found
Precuneus blood flow. Compared with placebo, the spermidine group showed a CBF increase of 4.9 ml/100 g/min in the precuneus (95% CI 1.0 to 8.9; P=.015; partial eta squared .11). That is a moderate effect size for a small sample, but the confidence interval is wide, so the true effect could be small.
Posterior cingulate. A similar direction appeared in the posterior cingulate gyrus (3.7 ml/100 g/min), but it did not reach conventional significance (95% CI -0.5 to 7.8; P=.08).
White-matter microstructure. FA in the cingulate gyrus white-matter bundle stayed stable with spermidine but declined with placebo (difference .016; P=.029). Lower FA is generally read as reduced fiber-tract organization, so "holding steady" is the interesting part. Still, this reflects the placebo group worsening as much as the treatment group improving.
Unrelated changes. CBF and FA changes were not substantially associated with each other, suggesting they may reflect separate processes, or simply noise.
What did not change
This part matters as much as the headline:
- No meaningful between-group differences in global or regional brain volume
- No differences in cortical thickness
- No differences in white-matter hyperintensities
- No association between regional MRI changes and memory performance
- No association with subjective cognitive complaints
- No association with plasma soluble intercellular adhesion molecule-1 (sICAM-1), a vascular inflammation marker
The parent SmartAge trial also did not show a memory benefit from spermidine. So the imaging signal currently has no behavioral counterpart.
How to read this honestly
It is exploratory. This is a secondary analysis, and the authors explicitly state the findings are preliminary and need independent confirmation. Many outcomes were tested across many brain regions. With multiple comparisons, a few nominal p-values around .015 to .03 can appear by chance, and the abstract does not suggest correction strong enough to rule that out.
The sample is small. Seventy-five people split across two arms gives limited power and unstable effect estimates, as the wide confidence intervals show.
Perfusion is an indirect marker. Higher blood flow in a region is not automatically beneficial. It could reflect improved vascular function, altered neural activity, or measurement variability. Without a link to cognition, its meaning remains unclear.
Biologically plausible, though. Spermidine is a polyamine linked in animal studies to autophagy, mitochondrial function, and vascular health. A perfusion and white-matter signal in regions vulnerable early in Alzheimer's-type changes, like the precuneus and posterior cingulate, fits that story. Plausible is not the same as demonstrated in humans.
Practical considerations
Dose. The trial used 0.9 mg of spermidine per day, a modest amount comparable to what dietary intake can supply. Higher doses were not tested here, so there is no basis to assume more is better.
Food sources. Spermidine occurs naturally in wheat germ, which is among the richest sources, along with aged cheese, soybeans and natto, mushrooms, legumes, and some whole grains. Supplements in trials are often wheat germ-derived extracts.
Who it might be for. The study population was older adults (60 to 90) with subjective cognitive decline. Nothing here supports spermidine as a treatment for dementia or as a memory enhancer in healthy adults. People with wheat allergy or celiac disease should check supplement sources, and anyone on medications or with medical conditions should consult a clinician first.
Takeaways
- Twelve months of 0.9 mg/day spermidine was linked to higher precuneus blood flow (+4.9 ml/100 g/min vs placebo) and more stable cingulate white-matter FA.
- No effects were seen on brain volume, cortical thickness, or white-matter hyperintensities.
- MRI changes were not tied to memory, subjective complaints, or sICAM-1.
- The parent trial found no memory benefit.
- Results are exploratory, based on 75 people, and need independent replication.
- Bottom line: an intriguing vascular signal worth following up, not a reason to expect cognitive gains today.
What comes next
The key tests are larger, pre-registered trials with imaging as a primary outcome, longer follow-up, and cognitive measures sensitive enough to detect change. If the perfusion effect replicates and eventually connects to clinical outcomes, spermidine could earn a place in brain-health strategies. Until then, it remains a promising but unproven candidate.
